[ad_1]
By Chris Wack
Pliant Therapeutics Inc. said it has seen positive interim results from a phase 2a clinical trial based on positron emission tomography imaging of PLN-74809 in patients with idiopathic pulmonary fibrosis.
The biotech company said that across four dose levels, all patients achieved a target commitment greater than 50% after a single dose of PLN-74809.
A target commitment of 50% was previously established in a phase 1b trial as a threshold for the predicted clinical anti-fibrosic effect. In addition, there was a dose and plasma concentration dependent response, with the two highest doses approaching target saturation.
The ongoing Phase 2a open-label PET imaging clinical trial is designed to assess target engagement levels achieved by PLN-74809 when administered in single doses of 60 mg, 120 mg, 240 mg or 320 mg in patients with IPF. The trial also assesses safety, tolerability and pharmacokinetics. At the end of a standard washout period, patients may consent to receive a second dose of PLN-74809 at a different dose level followed by a second post-dose PET.
The company said PLN-74809 was well tolerated at all doses. No serious adverse events reported.
Pliant shares were up 53%, to $ 29.63, in pre-market trading.
Write to Chris Wack at [email protected]
Source link
